Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $23.40 USD
Change Today +0.78 / 3.45%
Volume 133.8K
FLXN On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

flexion therapeutics inc (FLXN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $30.37
52 Week Low
08/4/14 - $11.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

flexion therapeutics inc (FLXN) Related Businessweek News

No Related Businessweek News Found

flexion therapeutics inc (FLXN) Details

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which is in placebo-controlled Phase III clinical trials to treat the patients with moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which is in Phase IIa clinical trials intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

29 Employees
Last Reported Date: 03/24/15
Founded in 2007

flexion therapeutics inc (FLXN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $675.3K
Co-Founder and Chief Medical Officer
Total Annual Compensation: $472.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $412.5K
Compensation as of Fiscal Year 2014.

flexion therapeutics inc (FLXN) Key Developments

Flexion Therapeutics, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Flexion Therapeutics, Inc. announced consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operations was $9.015 million against $6.435 million a year ago. Loss from operations before income tax was $9.173 million against $6.542 million a year ago. Net was $9.173 million against $6.542 million a year ago. Basic and diluted net loss per share was $0.43 against $0.86 a year ago.

Flexion Therapeutics, Inc. to Report Q1, 2015 Results on May 07, 2015

Flexion Therapeutics, Inc. announced that they will report Q1, 2015 results at 9:05 PM, GMT Standard Time on May 07, 2015

Flexion Therapeutics, Inc., Q1 2015 Earnings Call, May 07, 2015

Flexion Therapeutics, Inc., Q1 2015 Earnings Call, May 07, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLXN:US $23.40 USD +0.78

FLXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FLXN.
View Industry Companies

Industry Analysis


Industry Average

Valuation FLXN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLEXION THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at